Highlights

• Epiminder Ltd changed hands at $0.435 at 15:17 AEST on Wednesday 19 August 2026, up 4.82% on the day.

• No price-sensitive ASX announcement lodged on 18 or 19 August 2026 could be identified. Epiminder's most recent verified disclosures are from late July, and.

• Epiminder's news flow through 2026 has centred on the DETECT study, a US clinical and reimbursement study for its Minder system. The verified milestones.

• The near-term checkpoints are the next enrolment milestones, the September-quarter Appendix 4C for an updated cash position and burn rate, site activations toward the.

Epiminder Ltd changed hands at $0.435 at 15:17 AEST on Wednesday 19 August 2026, up 4.82% on the day. Volume was 349,560 shares at a relative volume of 1.08 — an ordinary session's turnover, not a rush. Market Capitalisation on the screen was $83.42 million, with trailing diluted EPS of -$0.18 and no price-to-earnings ratio, as expected for a pre-revenue medical device developer. The daily gain is modest. The context is not.

What is driving the move

No price-sensitive ASX announcement lodged on 18 or 19 August 2026 could be identified. Epiminder's most recent verified disclosures are from late July, and nothing dated this week appears on the company's own news feed. On our reading, Wednesday's gain is a continuation of a re-rating that began in early August. On 3 August 2026 the shares jumped 17.5% to $0.335 as the market absorbed evidence that patient recruitment in the company's pivotal US study was running ahead of schedule.

Recent developments and operating picture

Epiminder's news flow through 2026 has centred on the DETECT study, a US clinical and reimbursement study for its Minder system. The verified milestones: 31 May / 1 June 2026 — the study reached its 25th enrolment. 16 July 2026 — the study reached its 50th enrolment, which the company said was ahead of schedule. Late July 2026 — Epiminder lodged its Q4 FY26 quarterly activities report and Appendix 4C, alongside an FY26 investor presentation. The most recent quarterly for which detailed figures could be verified is the March 2026 quarter, reported on 2 May 2026. It showed: Cash of A$83.8 million at 31 March, down from A$89.5 million at 31 December. Quarterly net cash outflow of A$5.7 million, against A$25.2 million in the prior quarter. Funding sufficient to extend "well into calendar year 2028". 18 contracted sites and 15 patients enrolled at that point.

Numbers, opportunity and risks

From the TradingView snapshot: last price $0.435, up 4.82%, volume 349,560, relative volume 1.08, market capitalisation $83.42 million, trailing diluted EPS -$0.18. From verified filings and coverage: IPO price $1.50 (December 2025); gross raise A$125 million; cash A$83.8 million at 31 March 2026; March-quarter net outflow A$5.7 million; runway stated as extending well into calendar 2028; DETECT enrolment 50 of a 210 target as at 16 July 2026. The most striking number is the relationship between the two. Even on Kalkine's conservative estimate of roughly A$70 million of cash at 30 June, the market is valuing Epiminder's technology, intellectual property and clinical programme at only a modest premium to its bank balance. The gap between cash and market capitalisation is the core of the argument: buyers at these levels are acquiring a funded clinical programme for close to net cash.

What comes next

The near-term checkpoints are the next enrolment milestones, the September-quarter Appendix 4C for an updated cash position and burn rate, site activations toward the 25-centre target, and any update on the timing of the FDA G1 submission.

Bottom line

Epiminder's 4.82% gain on Wednesday was small and came on unremarkable volume — 1.08 relative volume is not conviction buying. No new announcement explains it.